The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years

CONCLUSION: Modestly higher RZV coverage in US adults 50-59 years could reduce the clinical burden associated with HZ and may result in societal cost savings. These findings demonstrate the potential value of increasing RZV vaccination in this population.PMID:37541822 | DOI:10.1016/j.vaccine.2023.07.025

Source: Herpes - August 4, 2023 Category: Infectious Diseases Authors: David Singer Ahmed Salem Nikita Stempniewicz Siyu Ma Sara Poston Desmond Curran Source Type: research